Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DV-601 + entecavir
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**DV-601 + entecavir** is a combination therapy consisting of DV-601 and entecavir, designed to treat chronic hepatitis B. DV-601 is a novel hepatitis B virus (HBV) capsid assembly modulator (CAM), while entecavir is a nucleoside analog reverse transcriptase inhibitor that blocks HBV DNA synthesis. The combination aims to achieve broader antiviral activity through dual mechanisms: inhibiting HBV DNA replication (via entecavir) and disrupting viral capsid formation/encapsidation (via DV-601), which may increase effectiveness and reduce resistance compared to monotherapy. Entecavir is marketed as Baraclude and is often used in combination regimens when monotherapy is insufficient or resistance has developed[1].
- Other names
- DV-601DV601DV 601entecavir
02
Targets
HBV Pol (Hepatitis B virus polymerase)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on DV-601 + entecavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DV-601 + entecavir.